Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47376 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2FPR2 | |
| SCHEMBL27758080 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2 | |
| SCHEMBL24129189 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL24127751 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL24129464 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL15014467 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL2627813 | 0.74 | SMN1; SMN2 (0.97) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL2627811 | 0.73 | SMN1; SMN2 (0.63) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL1646593 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL4395997 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | SMN1; SMN2 3682/4885GAA 1536/4885FPR2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.